Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311629 | 0.84 | LMNA (0.51) | LMNAPOLBSMN1; SMN2HRH2HRH1 | |
| SCHEMBL3303792 | 0.79 | LMNA (0.49) | LMNAPOLBSMN1; SMN2HRH2HRH1 | |
| SCHEMBL24666903 | 0.79 | SMN1; SMN2 (0.43) | LMNAPOLBSMN1; SMN2HRH2HRH1 | |
| SCHEMBL31540794 | 0.78 | GNAI3 (0.58) | LMNAPOLBSMN1; SMN2HRH2HRH1 | |
| SCHEMBL5156110 | 0.77 | LMNA (0.59) | LMNAPOLBSMN1; SMN2HRH2HRH1 | |
| SCHEMBL4477768 | 0.77 | SMN1; SMN2 (0.47) | LMNAPOLBSMN1; SMN2HRH2HRH1 | |
| SCHEMBL7449135 | 0.77 | POLB (0.63) | LMNAPOLBSMN1; SMN2HRH2HRH1 | |
| SCHEMBL11974037 | 0.76 | POLB (0.58) | LMNAPOLBSMN1; SMN2HRH2HRH1 | |
| SCHEMBL16256877 | 0.76 | LMNA (0.58) | LMNAPOLBSMN1; SMN2HRH2HRH1 | |
| SCHEMBL7339506 | 0.75 | LMNA (0.61) | LMNAPOLBSMN1; SMN2HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | LMNA 890/4885POLB 2618/4885SMN1; SMN2 4092/4885 |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | LMNA 890/4885POLB 2618/4885SMN1; SMN2 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.